Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Raising Finance During the COVID-19 Crisis (LSX)

Related Content

Update on Recent International Biosimilar Approvals

FDA Releases Draft Labeling Guidance for Biosimilar Products

Is it Biosimilar or Interchangeable? It Won’t Be Easy to Tell Under FDA’s Latest Draft Labeling Guidance

Update on mRNA Vaccine Patent Litigation

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022

UK’s Medicines Regulator Announces Guidance on the New International Recognition Procedure for the Approval of New Medicines from 1 January 2024

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year

Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders

Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines

Bloomberg Intelligence Podcast (Bloomberg)

Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.

Generate:Biomedicines Completes $273 Million Series C

Lauxera Capital Partners Invests €17 Million in BioLamina

Life Sciences

Technology